-
-
-
-
-
-
-
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
-
-
-
-
-
-
-
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation (MTAC)
-
-
-
-
-
67,940 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

